Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bortezomib + Daratumumab + Dexamethasone + Thalidomide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bortezomib||Velcade||Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov).|
|Daratumumab||Darzalex||JNJ-54767414||CD38 Antibody 7||Darzalex (Daratumumab) is a human antibody against CD38 that induces antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity against CD38-positive tumor cells (PMID: 30546360). Darzalex (Daratumumab) is FDA approved for multiple myeloma patients as a monotherapy or in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, or with bortezomib, melphalan, and prednisone, or with pomalidomide and dexamethasone, or with bortezomib, thalidomide and dexamethasone (FDA.gov).|
|Thalidomide||Thalomid||N-Phthalimidoglutamic acid imide||Thalomid (thalidomide) is a a racaemic glutamic acid analogue that has anti-inflammatory, anti-angiogenic, immunosuppressive, and anti-tumor activities (PMID: 15172781). Thalomid (thalidomide) is approved for use in combination with dexamethasone for patients with newly diagnosed multiple myeloma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||Bortezomib + Daratumumab + Dexamethasone + Thalidomide||FDA approved||Actionable||In a Phase III trial (CASSIOPEIA) that supported FDA approval, Darzalex (daratumumab) in combination with Velcade (bortezomib), thalidomide, and dexamethasone (VTd) resulted in improved stringent complete response at 100 days post autologous stem-cell transplantation compared to VTd (29%, 157/543 vs 20%, 110/542, OR=1.60, p=0.0010) in patients with newly diagnosed multiple myeloma (PMID: 31171419; NCT02541383).||detail... 31171419|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04352205||Phase II||Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Thalidomide||Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure||Recruiting|